Literature DB >> 21737551

Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis.

K K Mubarak1, A Montes-Worboys, D Regev, N Nasreen, K A Mohammed, I Faruqi, E Hensel, M A Baz, O A Akindipe, S Fernandez-Bussy, S D Nathan, V B Antony.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterised by myofibroblast proliferation leading to architectural destruction. Neither the origin nor the continued proliferation of myofibroblasts is well understood. Explanted human IPF lungs were stained by immunohistochemistry for calretinin, a marker of pleural mesothelial cells (PMCs). Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) lungs acted as controls. The number of PMCs per 100 nucleated cells and per photomicrograph was estimated along with the Ashcroft score of fibrosis. Mouse PMCs expressing green fluorescent protein (GFP) or labelled with nanoparticles were injected into the pleural space of mice given intranasal transforming growth factor (TGF)-β1. Mouse lungs were lavaged and examined for the presence of GFP, smooth muscle α-actin (α-SMA) and calretinin. Calretinin-positive PMCs were found throughout IPF lungs, but not in COPD or CF lungs. The number of PMCs correlated with the Ashcroft score. In mice, nanoparticle-laden PMCs were recoverable by bronchoalveolar lavage, depending on the TGF-β1 dose. Fluorescent staining showed α-SMA expression in GFP-expressing PMCs, with co-localisation of GFP and α-SMA. PMCs can traffic through the lung and show myofibroblast phenotypic markers. PMCs are present in IPF lungs, and their number correlates with IPF severity. Since IPF presumably begins subpleurally, PMCs could play a pathogenetic role via mesothelial-mesenchymal transition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737551     DOI: 10.1183/09031936.00141010

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  36 in total

Review 1.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

2.  miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2.

Authors:  Marta Fierro-Fernández; Óscar Busnadiego; Pilar Sandoval; Cristina Espinosa-Díez; Eva Blanco-Ruiz; Macarena Rodríguez; Héctor Pian; Ricardo Ramos; Manuel López-Cabrera; Maria Laura García-Bermejo; Santiago Lamas
Journal:  EMBO Rep       Date:  2015-08-27       Impact factor: 8.807

3.  Heterogeneity of Fibroblasts and Myofibroblasts in Pulmonary Fibrosis.

Authors:  David M Habiel; Cory M Hogaboam
Journal:  Curr Pathobiol Rep       Date:  2017-05-02

Review 4.  Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.

Authors:  Justin C Hewlett; Jonathan A Kropski; Timothy S Blackwell
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

Review 5.  New therapeutics based on emerging concepts in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Prathibha R Gajjala; Rajesh K Kasam; Satish K Madala
Journal:  Expert Opin Ther Targets       Date:  2018-11-28       Impact factor: 6.902

6.  Ezh2 restricts the smooth muscle lineage during mouse lung mesothelial development.

Authors:  Melinda Snitow; MinMin Lu; Lan Cheng; Su Zhou; Edward E Morrisey
Journal:  Development       Date:  2016-08-30       Impact factor: 6.868

7.  miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II.

Authors:  Qian Zhang; Hong Ye; Fei Xiang; Lin-Jie Song; Li-Ling Zhou; Peng-Cheng Cai; Jian-Chu Zhang; Fan Yu; Huan-Zhong Shi; Yunchao Su; Jian-Bao Xin; Wan-Li Ma
Journal:  Mol Ther       Date:  2017-01-26       Impact factor: 11.454

8.  EPAS1 promotes peritoneal carcinomatosis of non-small-cell lung cancer by enhancing mesothelial-mesenchymal transition.

Authors:  Qiang Zhen; Yaxiao Zhang; Lina Gao; Renfeng Wang; Weiwei Chu; Xiaojian Zhao; Zhe Li; Huixian Li; Bing Zhang; Baolei Lv; Jiabao Liu
Journal:  Strahlenther Onkol       Date:  2020-07-17       Impact factor: 3.621

Review 9.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 10.  Epithelial-mesenchymal transition in tissue repair and fibrosis.

Authors:  Rivka C Stone; Irena Pastar; Nkemcho Ojeh; Vivien Chen; Sophia Liu; Karen I Garzon; Marjana Tomic-Canic
Journal:  Cell Tissue Res       Date:  2016-07-27       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.